The UK and US have hammered out a major commercial pact that will preserve zero import taxes on British medicine exports being sold in the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to boost expenditure on pharmaceuticals through the public health system. This commitment guarantees that import taxes on these key goods will stay at nothing for a duration of 36 months.
This development comes after previous threats to significantly raise import taxes on patented pharmaceutical imports, with increases floated reaching double the cost.
"This deal with the Britain bolsters the worldwide climate for innovative medicines and brings much-needed fairness to transatlantic pharmaceutical trade," an announcement said.
Commercial Importance
Pharmaceuticals represent one of the the United Kingdom's largest goods shipped to the United States, which is clearly the primary buyer for major companies like GSK and AstraZeneca.
Trade data show that in the year to the end of last September, the UK shipped drugs valued at over eleven billion pounds to the US. This value made up 17.4% of British export trade in that period.
"This guarantee secures work, increases investment and sets the stage for the UK to emerge as a international leader for life sciences," a government official remarked.
Specific British Pledges
The pact includes several notable commitments from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new treatments to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to raise total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, refunds were more than twenty percent.
Broader Context
This agreement takes place against a long-running tension between the drug companies and the ministers over drug pricing and NHS adoption.
The disagreement were exacerbated by assertions that US consumers were charged a premium for the same drugs than people in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar investments have been directed toward US facilities.
The Science Minister acknowledged that the NHS had to spend more on drugs, noting that its expenditure on drugs had decreased as a percentage of its resources over the last ten years.
